Effective brain delivery technology via nasal administration

Through the combination of pH-sensitive bioreducible polymers and adenovirus vectors, nasal administration technology is used to bypass the blood-brain barrier, and efficient treatment and diagnosis of central nervous system diseases, neurodegenerative diseases and brain tumors are achieved, solving the problem of solving The problem of low drug delivery efficiency in the prior art is found.

CN114641517BActive Publication Date: 2024-11-15INDUSTRY UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080077252.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-07
Filing Date
2020-11-06
Publication Date
2024-11-15
Estimated Expiration
2040-11-06

AI Technical Summary

Technical Problem

The existing nasal administration technology is difficult to effectively bypass the blood-brain barrier, resulting in low drug delivery efficiency and poor treatment for central nervous system diseases, neurodegenerative diseases and brain tumors.

Method used

Using pH-sensitive bioreducing polymers, drug delivery bodies are delivered to the brain by nasal administration, using PEG-Pip-N,N'-cysamine bisacrylamide and arginine-conjugated polyethyleneimine (PEI)-formed PPA polymers combine with adenovirus vectors to achieve targeted drug delivery.

Benefits of technology

It improves the bioavailability of drugs, reduces side effects, and realizes effective treatment and diagnosis of central nervous system diseases, neurodegenerative diseases and brain tumors, significantly improving the distribution and efficacy of drugs in brain tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114641517B_ABST
    Figure CN114641517B_ABST
Patent Text Reader

Abstract

The present invention relates to an effective brain delivery technology via nasal administration. More specifically, the present invention provides an effect for diagnosing, preventing or treating central nervous system brain diseases, neurodegenerative diseases, or brain tumors by effectively delivering a pH-sensitive bioreductive PPA polymer that can be used as a drug delivery body to the brain via nasal administration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an effective brain delivery technology via nasal administration, which is used for diagnosing, preventing or treating central nervous system diseases, neurodegenerative diseases or brain tumors by effectively delivering pH-sensitive bioreductive polymers that can be used as drug delivery bodies to the brain via nasal administration. Background Art

[0002] Real-time and non-invasive imaging of lesions is highly suitable for the treatment of central nervous system or brain tumors. For example, non-invasive tracking and imaging of lesions can enable early detection through routine diagnostic procedures, thereby allowing timely intervention and leading to an overall improved prognosis for the patient.

[0003] Intra-nasal delivery has emerged as a novel delivery system that can bypass the blood-brain barrier, which is the greatest obstacle to the delivery of therapeutic agents for the treatment of central nervous system diseases.

[0004] Various substances have been developed to improve the efficiency of delivery to the brain via nasal administration, and the present invention utilizes a polymer as its delivery body. Summary of the invention

[0005] The object of the present invention is to provide a pH-sensitive bioreductive polymer that can be used as a drug delivery body and its pharmaceutical use.

[0006] In order to achieve the above object, the present invention provides a polymer represented by the following Chemical Formula 1:

[0007] [Chemical formula 1]

[0008]

[0009] In the above formula,

[0010] X is PEG having a molecular weight of 2000 to 10000 Da,

[0011] Y is Or arginine-conjugated PEI (polyethyleneimine), PEI is branched PEI,

[0012] n is 1 to 10.

[0013] The present invention also provides a composition for delivering a drug to the brain via nasal administration, which comprises the polymer represented by the above Chemical Formula 1 as a carrier for drug delivery.

[0014] The present invention also provides a drug delivery body comprising the polymer represented by the above Chemical Formula 1 and one or more drugs selected from therapeutic agents and diagnostic agents.

[0015] The present invention also provides a method for delivering a drug to the brain via nasal administration, comprising the step of nasally administering the above-mentioned drug delivery body to an individual.

[0016] The present invention also provides a method for treating any one of central nervous system diseases, neurodegenerative diseases or brain tumors, comprising the step of nasally administering the above-mentioned drug delivery body in a pharmaceutically effective amount to an individual in need thereof.

[0017] The pH-sensitive bioreductive polymer of the present invention bypasses the blood-brain barrier and improves the bioavailability of drugs through nasal administration, thereby reducing side effects by reducing the dosage of drugs.

[0018] In addition, the drug administered by the nasal cavity does not initially pass through the bloodstream for systemic circulation, but reaches the target lesion site in the brain, thereby minimizing the adverse side effects caused by overdose. In addition, the present invention can effectively deliver drugs to various parts of brain tissue, and is therefore suitable for the treatment of central nervous system diseases, neurodegenerative diseases or brain tumors. In addition, the pH-sensitive bioreductive polymer of the present invention is labeled as a diagnostic marker and delivered to the brain tissue by nasal administration, so that it can be used for the diagnosis of central nervous system diseases, neurodegenerative diseases or brain tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Shows in vivo fluorescence images of Ad / PPA-IR780.

[0020] Figure 2 It indicates that the Ad / PPA-IR780 complex has a strong antitumor effect on orthotopic glioblastoma.

[0021] Figure 3 Represents intravital IVIS imaging in various organs and intravital NIR and optical imaging of brain tissue.

[0022] Figure 4 The antitumor efficacy of various Ad / polymer complexes is shown.

[0023] Figure 5 The in vivo distribution of various Ad / polymer complexes is shown.

[0024] Figure 6 The antitumor efficacy of various Ad / polymer complexes in orthotopic brain tumors using bioluminescence imaging was demonstrated.

[0025] Figure 7The antitumor efficacy of various Ad / polymer complexes was compared.

[0026] Figure 8 The antitumor efficacy of Ad / PPA-IR780 according to various administration routes is shown.

[0027] Fig. 9 This indicates the potent therapeutic efficacy of oAd / PPA-IR780.

[0028] Fig.10 This indicates the potent therapeutic efficacy of oAd / PPA-IR780.

[0029] Fig.11 Figure 5 shows the concentration of PTX in different regions of brain tissue after nasal or intravenous administration of PPA-PTX-IR780 in a mouse model with brain tumors.

[0030] Fig.12 Figure 5 shows the concentration of PTX in different regions of brain tissue after nasal or intravenous administration of PPA-PTX-IR780 in a normal mouse model.

[0031] Fig.13 Represents the bioavailability of PTX in the brain of tumor-bearing mouse models or normal mice.

[0032] Fig.14 The graph shows the distribution of siRNA by brain region after nasal administration of siRNA-Cy5.5 / PPA-IR780 in a mouse model with glioblastoma.

[0033] Fig.15 Graph showing pDNA intensity versus time following nasal or intravenous administration of pDNA-FITC / PPA-IR780 in a mouse model with brain tumors.

[0034] Fig.16 A graph showing pDNA intensity versus time after intranasal or intravenous administration of pDNA-FITC / PPA-IR780 in a normal mouse model.

[0035] Fig.17 Represents the bioavailability of pDNA in the brain of tumor-bearing mouse models or normal mice.

[0036] Fig.18 The figure shows the distribution of pDNA by brain region after intranasal administration of pDNA-FITC / polymer complex in a normal mouse model.

[0037] Fig.19 The efficient delivery of the nasally administered oAd / PPA-Cu-64-DOTA-Herceptin complex was demonstrated by PET / CT imaging.

[0038] Fig. 20 The delivery efficiency of PPA-Erbitux administered intranasally in normal mice is shown.

[0039] Fig.21 Shown is the bioavailability of PPA-IR780-PTX after intranasal administration.

[0040] Fig. 22 The potent antitumor efficacy of intranasally administered PPA-PTX was demonstrated by MR imaging.

[0041] Fig.23 The results of H&E staining show the potent antitumor efficacy of intranasally administered PPA-PTX in the U87MG / Fluc orthotopic brain tumor model.

[0042] Fig.24 The potent antitumor efficacy of intranasally administered PPA-PTX was demonstrated in the U87MG / Fluc orthotopic brain tumor model. DETAILED DESCRIPTION

[0043] Next, the configuration of the present invention will be described in detail.

[0044] The present invention relates to a polymer represented by the following Chemical Formula 1.

[0045] [Chemical formula 1]

[0046]

[0047] In the above formula,

[0048] X is PEG having a molecular weight of 2000 to 10000 Da,

[0049] Y is Or arginine-conjugated PEI (polyethyleneimine), PEI is branched PEI,

[0050] n is 1 to 10.

[0051] The above Y can be further modified to have a primary amine group. The amine group can be used for conjugation of drugs or targeting moieties.

[0052] The polymer of Chemical Formula 1 of the present invention is a biodegradable and pH-sensitive compound that flows into the intracellular pH range (about pH 6.0) through a high absorption rate and targets the low pH hypoxic tumor microenvironment, and is composed of (i) an escapable portion from immune reactions, (ii) a chargeable portion, and (iii) a bioreducible portion containing a disulfide bond.

[0053] More specifically, the polymer of the above Chemical Formula 1 may also be referred to as PP or PPA.

[0054] If Y is When Y is arginine-conjugated PEI, the polymer of Chemical Formula 1 is represented by PP. That is, PEG-Pip-N,N'-cystaminebisacrylamide (CBA) [PEG-Pip-N,N'-cystaminebisacrylamide (CBA)]. In this specification, PP is also referred to as PPCBA. In the following embodiments, PP is also referred to as PP5, which refers to PP using 5kDa PEG. If Y is arginine-conjugated PEI, the polymer of Chemical Formula 1 is represented by PPA and is synthesized by the reaction of PEG-Pip-CBA (PP) and arginine-conjugated PEI (PEI-Arg). In this specification, PEI can be a branched PEI with a molecular weight of 1000 to 10000Da, and arginine can be conjugated to the primary amine of PEI. Y can be further modified to have a primary amine group. The amine group can be used for conjugation of a drug or a targeting portion. In the following embodiments, PPA can also be represented by PPA2 or PPA5, and refers to PPA using 2kDa or 5kDa PEG, respectively.

[0055] In the above chemical formula 1, PEG functions as an immune response evasion site, and arginine is a charge site that imparts a positive charge to the polymer. Arginine imparts a positive charge to the polymer, allowing it to bind to a negatively charged surface (e.g., a negatively charged surface of adenovirus) through ionic interactions to form a complex. N,N'-cystamine bisacrylamide (CBA) is a portion that functions as a bioreducing site containing a disulfide bond, and the portion that provides pH sensitivity to the polymer is piperazine (Pip).

[0056] For example, the synthesis process of PPA is briefly described as follows:

[0057] First, to synthesize PEI-Arg, arginine and polyethyleneimine were conjugated via an EDC / NHS coupling reaction.

[0058] To synthesize PEG-Pip-CBA (PP), PEG-acrylate (5kDa), N,N'-cystamine bisacrylamide (CBA) and piperazine (Pip) are reacted, and then PEI-Arg is added to synthesize PPCBA-PEI-Arg (PPA). Among them, PEG-acrylate includes various activated PEG-acrylates, for example, methoxy-, ortho pyridyldisulfide (OPSS)), COOH-, NH2-, or maleimide-PEG acrylate can be used. In a specific example, EPG-acrylate can be methoxy-PEG-acrylate. As an alternative, for PEGylation, other PEG derivatives can be used instead of PEG-acrylate.

[0059] More specifically, the polymer of the present invention is represented by the following Chemical Formula 2:

[0060] [Chemical formula 2]

[0061]

[0062] In the above formula,

[0063] Y is or arginine-conjugated PEI, PEI is branched PEI,

[0064] n is 1 to 10,

[0065] m is from 44 to 228 (PEG has a molecular weight of 2000 to 10000 Da).

[0066] Y is further modified to have a primary amine group. The amine group can be used for conjugation of drugs or targeting moieties.

[0067] The PPA polymer of the present invention is pH-sensitive and can deliver drugs to tumor cells, especially by targeting the microenvironment of tumor cells under hypoxic conditions. In addition, since the surface is positively charged, it can be used as a carrier for delivering drugs and the like into the body by binding to target components with negatively charged surfaces. Therefore, in addition to tumor cells, PPA polymers can also deliver drugs to targeted lesions.

[0068] In addition, the pH-sensitive polymer of the present invention can bypass the blood-brain barrier and flow into the brain tissue via nasal administration, and thus can be used as a drug carrier.

[0069] Therefore, as another embodiment of the present invention, the present invention provides a composition for delivering a drug to the brain via nasal administration, which comprises the polymer represented by the above Chemical Formula 1 as a carrier for drug delivery.

[0070] As another embodiment of the present invention, the present invention provides a drug delivery body comprising the polymer represented by the above Chemical Formula 1 and one or more drugs selected from therapeutic agents and diagnostic agents.

[0071] The PPA polymer of the present invention can be used as a carrier for drug delivery, and can target the microenvironment of the tumor, or deliver the drug to a targeted lesion site other than the tumor cell by combining with the target component, and can be delivered to the tumor cell by combining with the photosensitizer. When irradiated with near-infrared light in the wavelength range of 700-900nm, the tumor cells can be killed by photothermal therapy.

[0072] In addition, the PPA polymer of the present invention is bound to a diagnostic agent on its surface and can bypass the brain-blood barrier and flow into the brain tissue through nasal administration, and thus can be used for diagnosis of brain diseases.

[0073] The drug delivery system may be preferably a drug delivery system for nasal administration. The PPA polymer of the present invention bypasses the blood-brain barrier and flows into the brain tissue through nasal administration, thereby effectively delivering the drug.

[0074] The drug delivery body of the present invention may include a complex of a PPA polymer and a drug.

[0075] The therapeutic agent may be one or more selected from a gene delivery system, a photosensitizer, and a pharmaceutically active ingredient.

[0076] The gene delivery system can be (i) naked recombinant DNA molecules, (ii) plasmids, (iii) viral vectors, and (iv) liposomes or liposomes containing the naked recombinant DNA molecules or plasmids. form.

[0077] All gene delivery systems used in conventional gene therapy can be applied, and preferably plasmids can be used; adenovirus (Lockett LJ, et al., Clin. Cancer Res. 3: 2075-2080 (1997)), adeno-associated viruses (AAV, Lashford LS., et al., Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), retrovirus (Gunzburg WH, et al., Retroviral vectors. Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), lentivirus (Wang G. et al., J. Clin. Invest. 104 (11): R55-62 (1999)), herpes simplex virus (Chamber R., et al., Proc. Natl. Acad. Sci USA 92: 1411-1415 (1995)), vaccinia virus (Puhlmann M.et al., Human Gene Therapy 10:649-657 (1999)), reovirus, poxvirus, Semliki Forest virus, measles virus and other viral vectors; liposomes (Methods in Molecular Biology, Vol 199, SC Basu and M. Basu (Eds.), Human Press 2002) or liposomes containing the above naked recombinant DNA molecules or plasmids.

[0078] i. Adenovirus

[0079] Adenovirus is widely used as a gene delivery vector due to its medium genome size, easy operation, high titer, wide range of target cells and excellent infectivity. Both ends of the genome contain 100-200bp ITR (inverted terminal repeat), which is an essential cis element in DNA replication and packaging. The E1 region of the genome (E1A and E1B) encodes proteins that regulate transcription and host cell gene transcription. The E2 region (E2A and E2B) encodes proteins involved in viral DNA replication.

[0080] Among the adenovirus vectors currently developed, replication-deficient adenoviruses lacking the E1 region are widely used. On the other hand, the E3 region is removed from conventional adenovirus vectors to provide a site for inserting foreign genes (Thimmappaya, B. et al., Cell, 31: 543-551 (1982) and Riordan, J. R. et al., Science, 245: 1066-1073 (1989)). Therefore, the target nucleotide sequence to be transported into the cell is preferably an insertion-deleted E1 region (E1A region and / or E1B region, preferably E1B region) or E3 region, and more preferably an insertion-deleted E1 region. In this specification, the term "deletion" used in relation to the viral genome sequence includes not only complete deletion of the corresponding sequence, but also partial deletion.

[0081] Adenovirus has 42 different serotypes and subgroups AF. Among them, adenovirus type 2 and type 5 belonging to subgroup C are the most preferred starting materials for obtaining the adenovirus vector of the present invention. The biochemical and genetic information of adenovirus type 2 and type 5 is well known.

[0082] The foreign gene transferred by adenovirus replicates in the same manner as an episome, and thus has very low genetic toxicity to host cells. Therefore, it is judged that gene therapy using the adenovirus gene delivery system of the present invention is very safe.

[0083] ii. Retrovirus

[0084] Retroviruses are widely used as gene delivery vectors because they can insert their own genes into the host genome, transport large amounts of foreign genetic material, and infect a wide spectrum of cells.

[0085] In order to construct a retroviral vector, the target nucleotide sequence to be transported into the cell is inserted into the retroviral genome instead of the sequence inserted into the retrovirus, thereby producing a replication-defective virus. In order to produce virions, a packaging cell strain containing gag, pol and env genes but without LTR (long terminal repeat) and Ψ sequence was constructed (Mann et al., Cell, 33: 153-159 (1983)). When a recombinant plasmid containing the target nucleotide sequence to be transported, LTR and Ψ sequence is introduced into the above-mentioned cell strain, the Ψ sequence can produce RNA transcripts of the recombinant plasmid, and the transcript is packaged into a virus, and the virus is discharged into the culture medium (Nicolas and Rubinstein "Retroviral vectors," In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513 (1988)). The culture medium containing the recombinant retrovirus is collected and concentrated and used as a gene delivery system.

[0086] Gene delivery using second generation retroviral vectors was published. (Kasahara et al. Science, 266: 1373-1376 (1994)) A mutant of Moloney murine leukemia virus (MMLV) was created in which the EPO (erythropoietin) sequence was inserted into the envelope site to produce a chimeric protein with novel binding characteristics. The gene delivery system of the present invention can also be manufactured according to the construction strategy of the second generation retroviral vector described above.

[0087] iii. AAV vector

[0088] Adeno-associated virus (AAV) can infect non-dividing cells and is suitable for the gene delivery system of the present invention due to its ability to infect various types of cells. Detailed descriptions of the manufacture and use of AAV vectors are described in detail in U.S. Patents Nos. 5,139,941 and 4,797,368.

[0089] Studies on AAV as a gene delivery system are disclosed in LaFace et al, Viology, 162:483486 (1988), Zhou et al., Exp. Hematol. (NY), 21:928-933 (1993), Walsh et al, J. Clin. Invest., 94:1440-1448 (1994) and Flotte et al., Gene Therapy, 2:29-37 (1995).

[0090] Typically, AAV viruses are produced by co-transforming a plasmid containing a target gene sequence (target nucleotide sequence to be transported into cells) flanked by two AAV terminal repeat sequences (McLaughlin et al., J. Virol., 62: 1963-1973 (1988) and Samulski et al., J. Virol., 63: 3822-3828 (1989)) and an expression plasmid containing a wild-type AAV coding sequence without terminal repeat sequences (McCarty et al., J. Virol., 65: 2936-2945 (1991)).

[0091] iv. Other viral vectors

[0092] Other viral vectors can also be used as gene delivery systems in the present invention. Derived from vaccinia virus (Puhlmann M. et al., Human Gene Therapy 10:649-657 (1999); Ridgeway, "Mammalian expression vectors," In: Vectors: A survey of molecular cloning vectors and their uses. Rodriguez and Denhardt, eds. Stoneham: Butterworth, 467-492 (1988); Baichwaland Sugden, "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes," In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, 117-148 (1986) and Coupar et al., Gene, 68: 1-10 (1988)), lentivirus (Wang G. et al., J. Clin. Invest. 104 (11): R55-62 (1999)) or herpes simplex virus (Chamber R., et al., Proc. Natl. Acad. Sci USA 92:1411-1415 (1995)) can also be used as a transport system that can transport the target nucleotide sequence into the cell.

[0093] In addition, viral vectors include reovirus, poxvirus, Semliki Forest virus, and measles virus.

[0094] v. Liposome

[0095] Liposomes are automatically formed by phospholipids dispersed in an aqueous phase. Examples of successful transport of exogenous DNA molecules into cells by liposomes are disclosed in Nicolau and Sene, Biochim. Biophys. Acta, 721: 185-190 (1982) and Nicolau et al., Methods Enzymol., 149: 157-176 (1987). On the other hand, as the most used reagent in the transformation of animal cells using liposomes, there are liposomes (Lipofectamine, Gibco BRL). Liposomes containing the target nucleotide sequence to be transported interact with cells through mechanisms such as endocytosis, adsorption to the cell surface, or fusion with the plasma cell membrane, thereby transporting the target nucleotide sequence into the cell.

[0096] In one embodiment of the present invention, the gene delivery system may be a recombinant adenovirus.

[0097] As the various advantages of recombinant adenovirus as a gene delivery vector become more prominent, its frequency of use in cancer gene therapy has a trend of steadily increasing. In particular, when preparing to use gene therapy agents to treat cancer, it has the advantage of not requiring long-term and continuous expression of therapeutic genes. In addition, since the host immune response induced by the virus used as a vector is not a big problem or can even be advantageous, recombinant adenovirus is attracting much attention as a gene delivery body for cancer treatment.

[0098] The above-mentioned recombinant adenovirus may be a replication-deficient adenovirus or an oncolytic adenovirus.

[0099] The replication-defective adenovirus is recombined by inserting a therapeutic gene instead of the E1 gene (all or part) necessary for adenovirus replication, so that it cannot replicate in the cells into which the adenovirus has been introduced.

[0100] Oncolytic adenovirus is an adenovirus with a partial deletion of the E1B 55kDa gene, and can only proliferate in cells where p53 is functionally inactivated. In cancer cells where p53 function is inhibited, the virus proliferates actively, whereas in normal cells, the virus proliferates inhibited. Therefore, oncolytic adenovirus does not affect normal cells but can selectively kill only cancer cells, making it particularly advantageous in cancer treatment.

[0101] In one embodiment of the present invention, the recombinant adenovirus has an inactivated E1B 19kDa gene, an E1B 55kDa gene or an E1B 19kDa / E1B 55kDa gene, preferably an inactivated E1B 19kDa and E1B 55kDa gene.

[0102] In this specification, the term "inactivated" used in relation to a gene means that the gene is not normally transcribed and / or decoded, so that the function of the normal protein encoded by the gene is not expressed. For example, the inactivated E1B 19kDa gene is a gene that cannot produce active E1B 19kDa protein due to a mutation (replacement, addition, partial deletion or complete deletion) in the gene. When the E1B 19kDa gene is deleted, apoptosis may be increased, and when the E1B 55kDa gene is deleted, it has tumor cell specificity (reference: Korean Patent Application No. 2002-0023760).

[0103] According to a specific example of the present invention, the recombinant adenovirus of the present invention may contain an active E1A gene. The recombinant adenovirus containing the E1A gene has the property of being able to replicate. According to a more preferred specific example of the present invention, the recombinant adenovirus of the present invention contains an inactivated E1B 19kDa / E1B 55kDa gene and an active E1A gene.

[0104] In one embodiment of the present invention, the gene delivery system can be a replication-incompetent adenovirus that selectively kills tumors and lacks the E1 site.

[0105] In addition, the above-mentioned vector preferably further comprises a selection marker. The term "selection marker" in the present invention is used to facilitate the selection of cells transformed by introducing the shRNA expression cassette. As a selection marker that can be used in the vector of the present invention, as long as it is a gene that can be easily detected or determined whether it is introduced into the vector, there is no particular limitation, but as a representative marker that imparts drug resistance, nutritional requirements, resistance to cytotoxic agents or expression of surface proteins, etc., there are GFP (green fluorescent protein), puromycin (puromycin), neomycin (Neomycin: Neo), hygromycin (hygromycin: Hyg), histidinol dehydrogenase (histidinol dehydrogenase gene: hisD) or guanine phosphosphosribosyltransferase (guanine phosphosribosyltransferase: Gpt) and the like.

[0106] In addition, the photosensitizer may be selected from porphyrin compounds, chlorins compounds, bacteriochlorins compounds, phthalocyanine compounds, naphthalocyanine compounds and 5-aminolevuline ester compounds.

[0107] Preferably, it may be IR-780, Cu-64-DOTA, etc. which exhibit a photothermal effect under near infrared light in the wavelength range of 700-900 nm.

[0108] In addition, the type of the pharmaceutical active ingredient of the present invention is not particularly limited, and for example, it can be one or more selected from anticancer drugs, antibiotics, hormones, hormone antagonists, interleukins, interferons, growth factors, tumor necrosis factors, endotoxins, lymphotoxins, urokinase, streptokinase, tissue plasminogen activators, protease inhibitors, alkylphosphocholines, radioactive isotope-labeled components, surfactants, cardiovascular system drugs and nervous system drugs.

[0109] The anticancer drugs mentioned above include bevacizumab, temozolomide, nitrosourea, cisplatin, PCV (procarbazine + CCNU + vincristine), vinblastine, vincristine, vinflunine, vindesine), vinorelbine, cabazitaxel, docetaxel, larotaxel, ortataxel, paclitaxel, tesetaxel, ixabepilone, herceptin, erbitux, cyclosporine, Cyclophosphamide, doxorubicin, etoposide, topotecan, carboplatin, procarbazine, mechlorethamine, ifosfamide, melphalan, chlorambucil, bisulfan, dactinomycin, daunorubicin, bleomycin, plicomycin, mitomycin, tamoxifen, transplatinum, 5-fluorouracil, or methotrexate, etc.

[0110] The drug delivery body of the present invention can be used for the prevention or treatment of brain tumors through the tumor targeting of the PPA5 polymer, and can deliver drugs to the targeted lesion site by combining with other target components, so it can be used for the prevention or treatment of central nervous system diseases or neurodegenerative diseases.

[0111] Examples of the above central nervous system diseases include cognitive impairment, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorders, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile X syndrome, and the like.

[0112] The neurodegenerative disease may be ischemic stroke, traumatic brain injury, acute disseminated encephalomyelitis, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, mild cognitive impairment, Alzheimer's disease, Pick's disease, senile dementia, progressive supranuclear palsy, subcortical dementia, Wilson's disease, multiple infarct disease, arteriosclerotic dementia, AIDS-related dementia, cerebellar degeneration, spinocerebellar degeneration syndromes, Friedreich's ataxia, ataxia telangiectasia, epilepsy-related brain injury, spinal cord injury, restless legs syndrome. legs syndrome, Huntington's disease, Parkinson's disease, striatonigral degeneration, cerebral vasculitis, mitochondrial encephalomyopathies, neuronal ceroid lipofuscinosis, spinal muscular atrophies, lysosomal storage disorders of the central nervous system, leukodystrophies, urea cycle defect disorders, hepatic encephalopathies, renal encephalopathies, metabolic encephalopathies, porphyria, bacterial meningitis, viral meningitismeningitis, meningoencephalitis, prion diseases, poisonings with neurotoxic compounds, Guillain Barre syndrome, chronic inflammatory neuropathies, polymyositis, dermatomyositis, or radiation-induced brain damage.

[0113] The above-mentioned brain tumor (brain tumor or encephaloma) refers to a tumor occurring in the cerebral cortex and meninges. The above-mentioned brain tumor may be a glioma, an oligodendroglioma, a glioblastoma, a colloid cyst, an epidermoid cyst, a meningioma, a hemangioblastoma, a lymphoma, a pituitary adenoma, a metastatic tumor, or a combination thereof. For example, the glioma is a glioblastoma multiforme (GBM). The above-mentioned brain tumor may be a primary brain tumor or a tumor metastasized from other cancers.

[0114] In addition, the PPA polymer of the present invention can be labeled with a diagnostic agent (diagnostic marker), and the polymer labeled with the marker can be tracked in vivo, thereby achieving optical detection and imaging of central nervous system diseases, neurodegenerative diseases or brain tumors.

[0115] The above-mentioned diagnostic agent can be used without limitation as long as it is a substance that can detect and identify target cells. For example, near-infrared fluorescent substances that can penetrate living bodies include cyanine, allophycocyanin, fluorescein, tetramethylrhodamine, BODIPY or Alexa, etc.; calcium-47, carbon-11, carbon-14, chromium-51, cobalt-57, etc. Radioactive drugs such as lt-57, cobalt-58, erbium-169, fluorine-18, gallium-67, gallium-68, hydrogen-3, indium-111, iodine-123, iodine-131, technetium-99m, etc.; or MRI contrast agents, etc.

[0116] The drug delivery body of the present invention is applied to tissues or cells separated from the diagnostic object, and the PPA polymer and / or the diagnostic agent can be used to detect signals and obtain images. In order to detect such signals, a magnetic resonance imaging device or an optical imaging device can be used. The above-mentioned magnetic resonance imaging device is a device as follows: a biological body is placed in a strong magnetic field, irradiated with radio waves of a specific frequency, and energy is absorbed into the atomic nuclei of hydrogen, etc. present in the biological tissue. After being made into a high-energy state, the above-mentioned radio waves are interrupted to release the atomic nuclei of the above-mentioned hydrogen, etc., and this energy is converted into a signal, and the image is processed by a computer. Since magnetic waves or radio waves are not interfered by bones, clear three-dimensional tomographic images can be obtained from longitudinal, transverse, and arbitrary angles for tumors around hard bones or in the brain or bone marrow. In particular, the above-mentioned magnetic resonance imaging device is preferably a T2 spin-spin relaxation magnetic resonance imaging device.

[0117] The drug delivery body of the present invention may further include a pharmaceutically acceptable carrier, and may be formulated together with the carrier. The term "pharmaceutically acceptable carrier" in the present invention refers to a carrier or diluent that does not stimulate the organism and does not hinder the biological activity and characteristics of the administered compound. As an acceptable drug carrier in a drug delivery body formulated as a liquid phase solution, it is sterile and biocompatible, and saline, sterile water, Ringer's solution, buffered saline, albumin injection, glucose solution, maltodextrin solution, glycerol, ethanol, and a mixture of more than one of these components can be used. Other conventional additives such as antioxidants, buffers, and antibacterial agents can be added as needed. In addition, diluents, dispersants, surfactants, adhesives, and lubricants can be added to prepare injection preparations such as aqueous solutions, suspensions, emulsions; pills; capsules; granules or tablets.

[0118] As a dosage form for nasal administration containing the drug delivery body of the present invention as an active ingredient, it can be prepared into an injection form or a spray preparation such as an aerosol that can be inhaled through the respiratory tract. In order to prepare an injection dosage form, the drug delivery body of the present invention is mixed with a stabilizer or a buffer in water to prepare a solution or a suspension, and it can be prepared into a unit dosage preparation in an ampoule or a vial. When preparing a spray preparation such as an aerosol, a propellant or the like can be combined with an additive to disperse a water-dispersible concentrate or a wet powder.

[0119] The drug delivery body of the present invention can be sprayed to the nose-brain administration route through a drug delivery device for nose-brain delivery.

[0120] The drug delivery device for nose-to-brain delivery can be in the form of a known sprayer.

[0121] The drug delivery system of the present invention can be used as a single therapy, but can also be used together with other conventional chemotherapy or radiotherapy. When such combined therapy is implemented, the disease can be treated more effectively.

[0122] Therefore, as another embodiment of the present invention, the present invention provides a method for delivering a drug to the brain via nasal administration, which comprises the step of nasally administering the above-mentioned drug delivery body to an individual.

[0123] As another embodiment of the present invention, the present invention provides a method for treating any one of central nervous system diseases, neurodegenerative diseases or brain tumors, comprising the step of nasally administering the above-mentioned drug delivery body in a pharmaceutically effective amount to an individual in need thereof.

[0124] The term "pharmaceutically effective amount" in the present invention refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable in medical treatment. The appropriate dosage of the drug delivery body of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, gender, degree of disease symptoms, diet, administration time, excretion frequency and reaction sensitivity. Generally, a skilled doctor can easily determine and prescribe an effective dosage for the target treatment. Generally speaking, the drug delivery body of the present invention contains 1 x 10 5 -1Х10 15 pfu / ml of polymer or polymer-gene delivery system, photosensitizer or active pharmaceutical ingredient complex, usually 1×10 10 pfu were injected every two days for 2 weeks.

[0125] The term "individual" in the present invention may include animals such as horses, sheep, pigs, goats, camels, antelopes, dogs, or humans suffering from diseases, and their symptoms can be improved by administering the drug delivery body according to the present invention. By administering the drug delivery body according to the present invention to an individual, the disease can be effectively prevented and treated. The above-mentioned treatment method according to the present invention may be a method for treating animals other than humans, but is not limited to this. That is, considering that humans suffer from diseases whose symptoms can be improved by administering the drug delivery body according to the present invention, it can also be fully used for the treatment of humans.

[0126] The following is a detailed description of the experimental examples of the present invention. The following experimental examples are only illustrative of the present invention, and the scope of the present invention is not limited to the following experimental examples. This experimental example is used to make the disclosure of the present invention complete, and is provided to fully inform the technical personnel of the technical field to which the present invention belongs of the scope of the invention. The present invention is only limited by the scope of the claims.

[0127] Modes for Carrying Out the Invention

[0128] <Example 1> Synthesis of PPCBA-PEI-Arg

[0129] (1) Synthesis of poly(ethyleneimine)-arginine (PEI-Arg)

[0130] According to the reference, arginine was conjugated with polyethyleneimine (Journal of Colloid and Interface Science 348 (2010) 360-368, Biomaterials 31 (2010) 8759-8769). The carboxylic acid group of arginine amino acid (350 mg, 2.0 mmol) was activated by coupling with EDC / NHS (EDC, 384 mg, 2.0 mmol and NHS=230 mg, 2.0 mmol) reagent in PBS (phosphate saline buffer, pH=7.4 (PBS, 3.0 mL) at 4°C for 4 hours. Then, polyethyleneimine (PEI) (360 mg, 0.2 mmol) was added to activate arginine, and the reaction was carried out at room temperature for 18 hours. The reaction product was dialyzed against double distilled water for 1 day (MWCO 1.0 kDa) to remove unreacted compounds, and then lyophilized to obtain a white substance PEI-Arg. The chemical structure is shown by 1 H NMR (600 MHz, D2O) was used for confirmation. The characteristic peaks of PEI (2.0 to 3.0 ppm) and peaks of arginine (1.66-(-HCCH2CH2CH2NH-); 1.86(-HCCH2CH2CH2NH-); 3.24(-HCCH2CH2CH2NH-); 3.86(-HCCH2CH2CH2NH-) were confirmed.

[0131] (2) Synthesis of PPCBA-PEI-Arg (PPA)

[0132] To generate pH-sensitive and bioreducible polymers, mPEG-acrylate (125 mg, 0.025 mM (PEG = 5.0 kDa or 2.0 kDa; Laysan Bio, Inc)) and N,N'-cystaminebisacrylamide (71.5 mg, 0.275 mM) (PolySciences Inc., Warrington, PA) were dissolved in methanol (5.0 mL). Next, piperazine (19.5 mg) (Sigma-Aldrich) was added, and the reaction mixture was stirred at 50°C-60°C in the dark for 48 hours under 100% nitrogen atmosphere, and after cooling at room temperature, PEI-Arg (12 mg) was added. The final reaction mixture was stirred at room temperature for one day, and the polymer was finally dialyzed against double distilled water for one day (MWCO 3.5 kDa, Pro Spectrum, dialysis membrane) and then lyophilized to obtain PPCBA-PEI-Arg as a white substance. The chemical structure of PPCBA-PEI-Arg was determined by the resonance peaks at 2.3-2.8 and 3.6 ppm corresponding to the -N(CH2-CH2) methylene protons of piperazine and the -S-CH2-CH2-NH-CO- protons of CBA together with the characteristic peaks of mPEG and PEI-Arg. 1 The results were confirmed by H NMR (600 MHz, D2O).

[0133] (3) Cell lines and cell culture

[0134] The U87MG-Fluc cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM (Gibco BRL, Grand Island, NY) containing 10% FBS (Gibco BRL) and HEPES (GibcoBRL) at 37°C and 5% CO2.

[0135] (4) Adenovirus (Ad) preparation

[0136] Non-replicative Ad (dE1 / GFP) and oncolytic Ad (DWP418, RdB / IL-12 / Decorin or HE5cT-Rd19-k35 / Decorin; oAd) expressing GFP (green fluorescent protein) were used under the regulation of the CMV promoter at the E1 site, and basically the same method as that described in previous studies by the inventors of the present invention was used (Kim, E. et al. Hum. Gene Ther. 2003, 14, 14151428; Kim, J Hetal. J. Natl. Cancer Inst. 2006, 98, 14821493; Choi, J Wet al. Gene Ther. 2013, 20, 880892; Kim, PH et al. Biomaterials 2011, 32, 93289342). All Ads were propagated in HEK293 cells and then purified using CsCl (Sigma, St Louis, MI) gradients. 260 In the measurement, the absorbance 1 is equal to 10 12 The number of viral particles (VP) was calculated by VP / ml. The virus titers (Infectious titers, PFU / mL) were determined by limiting dilution assay on HEK293 cells. The virus particle / PFU ratios of dE1 / GFP and DWP418 were 29:1 and 81:1, respectively. MOI was calculated based on the virus titers.

[0137] (5) Preparation of Ad / PPA complex

[0138] To prepare Ad / PPA complex, Ad particles (2×10 10 VP / PBS, pH 7.4) was mixed with different concentrations of PPA polymer. As a result, the molar ratio of Ad particles per polymer was 1 x 10 5 and 1Х10 6 The solution was incubated at room temperature for 30 minutes before use.

[0139] (6) Statistical analysis

[0140] Data were expressed as mean ± standard deviation (SD). Statistical analysis was performed by two-tailed Student's t test (SPSS 13.0 software; SPSS, Chicago, IL), and P values ​​less than 0.05 were considered statistically significant.

[0141] <Experimental Example 1> In vivo fluorescence images of Ad / PPA-IR780

[0142] To analyze the biodistribution of Ad / PPA-IR780 complexes, the complexes were injected via the nasal route, and NIR imaging was performed at 5 minutes, 6 hours, 12 hours, 18 hours, 24 hours, and 48 hours after administration.

[0143] Figure 1 It was shown that the signal remained similar from 5 minutes to 18 hours after injection, and then gradually decreased in a time-dependent manner until 48 hours. As the Ad / PPA-IR780 complex flowed into the tumor tissue, much fluorescence signal remained in the tumor-bearing brain area: the maximum fluorescence intensity in the tumor area was reached 5 minutes after irradiation. This result indicates that the Ad / PPA-IR780 complex is a therapeutic agent suitable for targeting brain tumors through the nasal route.

[0144] <Experimental Example 2> Strong anticancer effect of Ad / PPA-IR780 complex

[0145] To construct a brain tumor model, human glioblastoma cell line U87MG-Fluc stably expressing the firefly luciferase gene was stereotaxically injected into the brain using a Hamilton syringe. To non-invasively monitor tumor growth, bioluminescence imaging was performed every 6 days. After intranasal injection of Ad / PPA5-IR780 complex on day 21, brain tumors were laser irradiated 6 hours after administration.

[0146] like Figure 2 As shown, on the 30th day after tumor cell injection, in the presence of Ad / PPA5-IR780 (7.26 × 10 6 The luciferase signal obtained in the orthotopic brain tumors of mice treated with p / s was significantly lower than that observed in the vehicle-treated group and showed a significant increase compared with PBS (9.48 × 10 8 The tumor fluorescence intensity was 131-fold lower than that of PPA5 / IR780. This result indicates that Ad / PPA5-IR780 complex can induce tumor growth inhibition of highly cohesive orthotopic glioblastoma.

[0147] <Experimental Example 3> In vivo imaging for tumor targeting and anti-tumor effect monitoring

[0148] In vivo bioluminescence imaging was performed to evaluate the fluorescence intensity of orthotopic tumors.

[0149] like Figure 3 As shown, compared with the PBS-treated group (1.26 × 10 9 p / s) compared with Ad / PPA5-IR780-treated group (7.64Х10 6 The fluorescence intensity of p / s) was 165 times lower. This result confirmed the potent antitumor effect of the nasally administered Ad / PPA5-IR780 complex.

[0150] In addition, the potent antitumor efficacy of the Ad / PPA5-IR780 complex was reconfirmed by in vivo NIR imaging and optical imaging comparison.

[0151] <Experimental Example 4> Antitumor efficacy and in vivo distribution of Ad / PPA-IR780

[0152] The therapeutic efficacy and biodistribution profile of various nasal administrations of nanocomplexes of Ad and various types of IR780-conjugated polymers were compared using the U87MG-Fluc orthotopic glioblastoma model. All treatments were administered via the nasal route on day 6 after cell injection. For all tumors, laser irradiation was performed at 6 hours after nasal administration of the treatment.

[0153] like Figure 4 As shown, on day 13 after tumor cell injection, the luciferase signal obtained from orthotopic tumors of mice administered Ad / PPA5-IR780, Ad / PPA2-IR780, and Ad / PP-IR780 was reduced by PP.

[0154] To evaluate the biodistribution profile of various Ad / polymer complexes in vivo, NIR imaging was performed every 24 h after the first intranasal administration of therapeutic agents on day 6 after tumor cell injection.

[0155] like Figure 5 As shown, mice treated with Ad / PPA2-IR780 or Ad / PPA5-IR780 showed higher fluorescence intensity in brain tissue compared with mice treated with Ad / PAMAM(G2)-IR780; after administration of Ad / PAMAM(G2)-IR780, little or no fluorescence was detected in the brain region. This result indicates that effective brain delivery via nasal injection is a general function of PPA-based polymers.

[0156] <Experimental Example 5> Anti-tumor efficacy of Ad / PPA-IR780: bioluminescence imaging

[0157] On day 6 after cell injection, the establishment of orthotopic brain tumors was confirmed by bioluminescence imaging. 6 p / s) were injected intranasally 3 times every 3 days with 20 μl of PBS, naked Ad (5×10 10 VP), Ad / APP (APP disclosed in Biomaterials 33 (2012) 8122-8130), Ad / PP5-PTX-Erbitux or Ad / PPA5-IR780 (1x10 5 , 1 x 10 6; polymer:Ad molar ratio). Six hours after intranasal administration, all tumors were irradiated with laser.

[0158] like Figure 6 As shown, on the 20th day after tumor cell injection, Ad / PPA5-IR780 (1×10 5 The luciferase signal obtained in orthotopic tumors of mice treated with Ad / APP, Ad / PP5-PTX-Erbitux, or Ad / PPA5-IR780 (1×10 6 Compared with the PP and PPA, the pH-sensitive polymers (PP and PPA) showed 3.40-, 2.32-, or 1.44-fold higher therapeutic efficacy, respectively. These results indicate that PP-based pH-sensitive polymers (PP and PPA) can effectively deliver Ad to the brain via nasal injection.

[0159] <Experimental Example 6> Antitumor efficacy of Ad / PPA-IR780 and different administration routes

[0160] To compare the antitumor effects of different Ad / polymer complexes, Ad / PAMAM-PEG, Ad / PPSA (PPSA disclosed in KR10-2016-0103078), Ad / APP or Ad / PPA5-IR780 were intranasally administered to mice three times every three days. One group of mice received Ad / PPA5-IR780 via the intravenous route (named Ad / PPA5-IR780 (IV) group). After all tumors were treated, laser irradiation was performed at 6 h.

[0161] like Figure 7 As shown, on day 26 after tumor cell injection, the luciferase signal obtained from the orthotopic tumors of mice treated with Ad / PPA5-IR780 (IN injection) was significantly lower than that of the other groups, showing 30.5-, 29.5-, 9.66-, or 27.9-fold lower tumor fluorescence compared to the groups treated with Ad / PAMAM-PEG, Ad / PPSA, Ad / APP, or Ad / PPA5-IR780 (IV injection), respectively, indicating that PPA5-IR780-mediated nasal delivery induced a better therapeutic efficacy compared with intravenous delivery.

[0162] In addition, if Figure 8As shown in the figure, as a result of studying the in vivo distribution, the fluorescent signal obtained from Ad / PPA5-IR780 (IN injection) was detected in the brain throughout the observation period, whereas no signal was detected in the brain tissue when Ad / PPA5-IR780 was intravenously administered. This suggests that nasal administration is important for the accumulation of Ad / PPA5-IR780 in brain tumors and its potent antitumor effect.

[0163] <Experimental Example 7> Potent therapeutic efficacy of oAd / PPA-IR780 in orthotopic brain cancer model

[0164] To evaluate the combined therapeutic efficacy of oncolytic Ad (oAd) and photothermal therapy using IR780 in vivo, oAd / PPA5-IR780 was injected intravenously (IV) or PBS, oAd, or oAd / PPA5-IR780 was injected intranasally (IN) into orthotopic brain tumors expressing luciferase. At 24 hours after injection, the tumors were irradiated with 808 nm laser for 3 minutes.

[0165] like Fig. 9 As shown, the combination of intranasal administration of oAd / PPA5-IR780 and laser irradiation induced a significantly higher antitumor effect compared with the other groups. 5 + / -2.1Х10 5 The luciferase signal obtained in the orthotopic brain tumors of mice treated with oAd / PPA5-IR780 (IN) and oAd / PPA5-IR780 (IN) was significantly attenuated compared with that in other treatment groups (P < 0.01), and was significantly different from that in the laser (6.6 × 10 7 + / -2.7Х10 7 p / s) and PBS treatment, no laser (4.0Х10 7 + / -8.6Х10 6 p / s) treated with oAd / PPA5-IR780(IV), laser (4.8Х10 7 + / -2.4Х10 7 p / s) and oAd processing, or laser-free (7.3Х10 6 + / -2.1Х10 6 p / s) treated with oAd / PPA5-IR780(IN) showed 67.5-, 40.8-, 101.8-, 49.2-, or 7.5-fold lower luciferase signals, respectively ( Fig.10 ). These results confirm the potent therapeutic efficacy of oAd / PPA5-IR780 combined with laser treatment after intranasal administration.

[0166] <Experimental Example 8> Distribution of PTX in brain tissue after nasal administration of PPA-IR780-PTX

[0167] To determine whether PTX conjugated to PPA-IR780 polymer can be effectively delivered to brain tissue, PTX-conjugated polymer mutants (PPA5-PTX-IR780) were administered by either intravenous or nasal routes. Brain tissue was obtained at 0.5h, 1h, 2h, and 6h after injection, and the amount of PTX in different anatomical regions of brain tissue was determined by LC-MS / MS.

[0168] like Fig.11 As shown in the figure, in a mouse model with brain tumor, the amount of PTX in the brain subregions increased irregularly within 0.5 h and reached normal at 2 h after intranasal injection. 2 h after intranasal injection, the concentration of PTX in the tumor was the highest in the brain subregions.

[0169] In a normal mouse model, intranasal injection of PPA5-PTX-IR780 induced an efficient influx of PTX into the brain tissue, comparable to that of Fig.11 Similar results were observed in tumor-bearing mice in Fig.12 ); similar in vivo distribution patterns were observed in both mice, but the total amount of PTX in normal mice was slightly lower compared to tumor-bearing mice. These results indicate that the presence of a tumor is not necessary for effective brain delivery of PPA5-PTX-IR780. Importantly, these results suggest that the PPA5-IR780 polymer backbone can be utilized as a drug delivery agent for the treatment of central nervous system diseases, neurodegenerative diseases, or brain tumors.

[0170] After nasal delivery of PPA5-PTX-IR780, Fig.11 and Fig.12 The values ​​obtained in the calculation of DTP (nose-to-brain direct transport, nose to brain direct delivery) and DTE (drug targeting efficiency, drug targeting efficiency) are used to analyze the DTP (nose to brain direct delivery) efficiency of PTX. DTP% represents the ratio of drugs delivered directly to the brain through the olfactory pathway. PPA5-PTX-IR780 showed the highest DTE% (1620.95+ / -38.81 in the tumor model and 1019.17+ / -28.39 in the normal model) and DTP% (93.83+ / -0.97 in the tumor model and 90.18+ / -0.96 in the normal model). The administration of PPA5-PTX-IR780 by the nasal route is effectively delivered through the olfactory area of ​​the nasal cavity, thereby showing better delivery of therapeutic agents to the brain than intravenous injection.

[0171] like Fig.13 As shown, when comparing the tumor model to the normal model, the amount of PTX delivered to the brain via the nasal route was higher in the tumor model.

[0172] <Experimental Example 9> Brain distribution of siRNA after nasal administration of siRNA-Cy5.5 / PPA-IR780

[0173] To evaluate whether siRNA can be delivered nasally via PPA5-IR780 polymer, Cy5.5-labeled siRNA (siRNA-Cy5.5) was complexed with PPA5-IR780 for nasal administration. The presence of siRNA-Cy5.5 in brain tissue was tested using a fluorescence reader at 0.5h, 1h, 2h, and 6h after injection.

[0174] like Fig.14 As shown in the figure, the fluorescence intensity of Cy5.5-labeled siRNA administered intranasally reached the highest level in the orthotopic brain tumor after 2 hours of irradiation; the intensity in the tumor area at this time was higher than that observed in all other areas of the brain. These results indicate that using PPA-IR780 as a delivery vehicle, siRNA can also be effectively delivered to tumors via the nasal route.

[0175] <Experimental Example 10> Brain distribution of pDNA after nasal administration of pDNA-FITC / PPA-IR780

[0176] In order to determine whether pDNA is delivered to the brain via the nasal cavity and to evaluate its delivery efficiency, FITC-labeled pDNA (pDNA-FITC) was complexed with PPA5-IR780 for nasal delivery. The pDNA-FITC / PPA5-IR780 complex was administered via intravenous and nasal routes. The presence of pDNA in brain tissue was tested using a fluorescence reader at 0.5h, 1h, 2h, and 6h after injection.

[0177] like Fig.15 As shown, significantly higher levels of FITC-labeled pDNA were observed in different parts of the brain after intranasal administration compared with intravenous administration. Importantly, the highest amount of pDNA was detected in tumor tissue 2 to 6 hours after injection, confirming that PPA5-IR780 promotes good pDNA influx into tumors.

[0178] In a normal mouse model, intranasal administration of pDNA-FITC / PPA5-IR780 induced an efficient influx of pDNA into brain tissue, whereas Fig.15 Similar results were observed in tumor-bearing mice ( Fig.16); similar biodistribution patterns were observed in both mice, but the total amount of pDNA in normal mice was slightly lower than that in tumor-bearing mice ( Fig.17 ). These results indicate that the presence of a tumor is not necessary for efficient brain delivery of pDNA by PPA5-IR780.

[0179] To evaluate which components of the PPA5-IR780 polymer are important for efficient delivery to the brain via the nasal route, several polymer derivatives of PPA5-IR780 without either the pH-reactive or IR780 moieties were generated. For the generation of derivatives without pH-reactive, piperazine as the pH-reactive moiety was replaced with a dithiothreitol (DTT) moiety that is not pH-reactive, thereby producing P(DTT)PA5-IR780. In addition, control polymers without photosensitizer were produced for both PPA5-IR780 and P(DTT)PA5-IR780, ultimately producing PPA5 and P(DTT)PA5 polymers, respectively. To compare the brain delivery efficiency of PPA5-IR780 and its derivatives without one or both functional moieties, pDNA-FITC was complexed with P(DTT)PA5, P(DTT)PA5-IR780, PPA5, or PPA5-IR780 polymers and then administered via the nasal route. At 0.5 h, 1 h, 2 h and 6 h after injection, the presence of pDNA in different areas of brain tissue was tested using a fluorescence reader.

[0180] like Fig.18 As shown, the FITC intensity was higher in mice treated with pDNA-FITC complexed with pH-responsive polymers (Groups 4 and 5) compared to the pDNA-FITC complexed with non-pH-responsive polymers (Groups 2 and 3). In addition, these results indicate that the brain influx efficiency of nasally administered pDNA / polymer complexes is independent of the photosensitive IR780 moiety, such as Groups 2 and 4 showed similar accumulation in different regions of brain tissue as Groups 3 and 5. Moreover, these results indicate that pH sensitivity is important for efficient polymer-mediated delivery of therapeutic agents via the nasal route.

[0181] <Experimental Example 11> Effective delivery of oAd / PPA-Cu-64-DOTA-Herceptin complex via nasal administration: PET / CT imaging

[0182] The efficiency of delivery of oAd / PPA-Cu-64-DOTA-Herceptin complex to the brain via nasal, intraperitoneal, and intravenous administration was determined by PET / CT imaging.

[0183] like Fig.19As shown, at 1 h after injection, nasal delivery showed the strongest signal in the brain region compared with other delivery methods.

[0184] <Experimental Example 12> Delivery of PPA-Erbitux in Normal Mice

[0185] Using LC-MS / MS experiments, the delivery efficiency of PPA conjugated with therapeutic antibodies to the brain was compared when administered intravenously and intranasally.

[0186] like Fig. 20 As shown, the combination of therapeutic antibodies and PPA5 can effectively deliver to the brain in the experimental group of nasal administration compared with the delivery of PBS or intravenous administration (IV) in the control group. In addition, the drug administration efficiency in brain tissue was compared over time, and the highest ratio was detected 2 hours after administration, which was 20% of the initial administration amount.

[0187] <Experimental Example 13> Bioavailability of PPA-IR780-PTX after nasal administration

[0188] The delivery efficiency of PPA-IR780 combined with PTX as a therapeutic drug to the brain was compared by LC-MS / MS experiments when administered intravenously and intranasally.

[0189] like Fig.21 As shown, PTX was successfully delivered to different regions of the brain via nasal delivery. In addition, a high rate of up to 12% of the initial dose was detected in brain tissue.

[0190] <Experimental Example 14> The powerful anti-tumor effect of PPA-PTX: MR imaging

[0191] like Fig. 22 As shown, by MR imaging, nasal delivery of PPA5-PTX showed better antitumor efficacy than PTX IV delivery and PTXI.N. delivery, and PPA5-PTX (IN) induced complete regression of brain tumors.

[0192] In addition, in the U87MG / Fluc orthotopic brain tumor model, H&E staining was performed on day 13 after injection, and the results showed that a dose of 1 / 25 of the PTX concentration (IN delivery) induced complete regression of brain tumors ( Fig.23 ).

[0193] In addition, if Fig.24 As shown, in the U87MG / Fluc orthotopic brain tumor model, nasal delivery of PPA5-PTX showed better antitumor efficacy than PTX IV delivery and PTX IN delivery, and a dose of 1 / 25 of the PTX concentration (IN delivery) showed better efficacy than intravenous delivery.

[0194] Possibility of Industrial Application

[0195] The present invention can be applied to the diagnosis and treatment of central nervous system diseases, neurodegenerative diseases or brain tumors.

Claims

1. Use of the polymer of the following chemical formula 1 for preparing a drug delivery carrier for nasal administration, wherein the drug delivery carrier comprises one or more drugs selected from therapeutic agents and diagnostic agents: Chemical formula 1 In the formula, X is PEG having a molecular weight of 5000 to 10000 Da, Y is arginine-conjugated polyethyleneimine PEI, wherein the polyethyleneimine PEI is a branched PEI, and n is 1 to 10.

2. The use according to claim 1, wherein The polymer and the drug are contained in the form of a complex.

3. The use according to claim 1, wherein The therapeutic agent is one or more selected from a gene delivery system, a photosensitizer and a pharmaceutically active ingredient.

4. The use according to claim 3, wherein The gene delivery system is in the form of (i) naked recombinant DNA molecules, (ii) plasmids, (iii) viral vectors, and (iv) liposomes or liposomes containing the naked recombinant DNA molecules or plasmids.

5. The use according to claim 4, wherein The viral vector is one or more selected from recombinant adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, herpes simplex virus, vaccinia virus, reovirus, poxvirus, Semliki Forest virus and measles virus.

6. The use according to claim 3, wherein The photosensitizer is one or more selected from the group consisting of porphyrin compounds, chlorin compounds, bacteriochlorin compounds, phthalocyanine compounds, naphthalocyanine compounds, and 5-aminolevulinic acid ester compounds.

7. The use according to claim 3, wherein The active ingredient of the drug is one or more selected from anticancer drugs, antibiotics, hormones, hormone antagonists, interleukins, interferons, growth factors, tumor necrosis factors, endotoxins, lymphotoxins, urokinase, streptokinase, tissue plasminogen activators, protease inhibitors, alkylphosphocholines, radioactive isotope labeled components, surfactants, cardiovascular system drugs and nervous system drugs.

8. The use according to claim 7, wherein The anticancer drug is one or more selected from bevacizumab, temozolomide, nitrosourea, cisplatin, PCV, vinblastine, vincristine, vinflunine, vindesine, vinorelbine, cabazitaxel, docetaxel, larotaxel, ortataxel, paclitaxel, tesetaxel, ixabepilone, Herceptin, erbitux, cyclophosphamide, doxorubicin, etoposide, topotecan, carboplatin, procarbazine, nitrogen mustard, ifosfamide, melphalan, chlorambucil, busulfan, dactinomycin, daunorubicin, bleomycin, primycin, mitomycin, tamoxifen, trans-platinum, 5-fluorouracil and methotrexate, and the PCV is procarbazine+CCNU+vincristine.

9. The use according to claim 1, wherein The drug delivery body is used for the prevention or treatment of any one of central nervous system diseases, neurodegenerative diseases or brain tumors.

10. The use according to claim 9, wherein The central nervous system disease is any one selected from cognitive impairment, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down syndrome, Rett syndrome and fragile X syndrome.

11. The use according to claim 9, wherein The neurodegenerative disease is selected from ischemic stroke, traumatic brain injury, acute disseminated encephalomyelitis, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, mild cognitive impairment, Alzheimer's disease, Pick's disease, progressive supranuclear palsy, subcortical dementia, Wilson's disease, multiple infarction, arteriosclerotic dementia, AIDS-related dementia, cerebellar degeneration, spinocerebellar degeneration complex, Friedreich's ataxia, telangiectasia ataxia, epilepsy-related brain injury, spinal cord injury, restless legs syndrome, Huntington's disease, Parkinson's disease, striatonigral degeneration, cerebral vasculitis, mitochondrial encephalomyopathy, neuronal ceroid lipofuscinosis, spinal muscular atrophy, lysosomal storage diseases associated with the central nervous system, leukodystrophy, urea cycle deficiency disorders, hepatic encephalopathy, renal encephalopathy, metabolic encephalopathy, porphyria, bacterial meningitis, viral meningitis, meningoencephalitis, prion disease, poisoning by neurotoxic compounds, Guillain-Barré syndrome, chronic inflammatory neuropathy, polymyositis, dermatomyositis, and any of the brain damage caused by radiation.

12. The use according to claim 9, wherein The brain tumor is a glioma, an oligodendroglioma, a glioblastoma, a colloid cyst, an epidermoid cyst, a meningioma, a hemangioblastoma, a lymphoma, a pituitary adenoma, a metastatic tumor, or a combination thereof.

13. The use according to claim 1, wherein The diagnostic agent is a near-infrared fluorescent substance, a radiopharmaceutical or a contrast agent.